Pharmacogenomic Effect/ADR for Atomoxetine (DBSNPE006028)
- Identifier
- DBSNPE006028
- Drug
- Atomoxetine (DB00289)
- Interacting Gene/Enzyme
- Cytochrome P450 2D6
- Gene Name
- CYP2D6
- UniProt ID
- P10635
- Defining Change(s)
2549delA rs35742686 - Allele Name
- CYP2D6*3
- Genotype(s)
- (-;-)
- Type(s)
- Effect Directly Studied
- Groups
- Non-functional CYP2D6
- Description
- The presence of this genotype in CYP2D6 may be associated with reduced metabolism of atomoxetine and more frequent occurrence of adverse events.
- References
- Fijal BA, Guo Y, Li SG, Ahl J, Goto T, Tanaka Y, Nisenbaum LK, Upadhyaya HP: CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. J Clin Pharmacol. 2015 Oct;55(10):1167-74. doi: 10.1002/jcph.530. Epub 2015 Jun 14. [Article]